ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...
